Evoke Pharma announces warrant proceeds, board expansion

Evoke Pharma received approximately $3.0 million in gross proceeds from the amendment and exercise of existing warrants. The approximately $3.0 million in gross proceeds will be used to support working capital and general corporate purposes, including advancing the commercial efforts for GIMOTI. Details of the exercised warrants can be found in the corresponding SEC filing. No new warrants were issued with these transactions which closed on September 30, 2024. As part of this transaction, Nantahala Capital Management, an existing investor and warrant holder, has been granted the right to nominate two members to the company’s Board of Directors.